{"id":5878,"date":"2012-01-13T16:19:00","date_gmt":"2012-01-13T16:19:00","guid":{"rendered":"https:\/\/aspree.org\/aus\/?p=5878"},"modified":"2021-08-24T02:09:19","modified_gmt":"2021-08-24T02:09:19","slug":"australia-way-ahead-on-aspirin-research","status":"publish","type":"post","link":"https:\/\/aspree.org\/aus\/australia-way-ahead-on-aspirin-research\/","title":{"rendered":"Australia ‘way ahead’ on aspirin research"},"content":{"rendered":"\r\n

ASPREE leads quest for answers in older adults, says Investigator<\/h2>\r\n\r\n\r\n\r\n

 <\/p>\r\n\r\n\r\n\r\n

 <\/p>\r\n\r\n\r\n\r\n

\"Fair\r\n
Above: Professor Mark Nelson, a chief investigator to the ASPREE trial in Tasmania, said Australia is already studying the benefit versus risk of daily low-dose aspirin use in healthy older adults. <\/em><\/figcaption>\r\n<\/figure>\r\n\r\n\r\n\r\n

“Recent\u00a0headlines\u00a0that ‘a daily dose of aspirin may do more harm than good\u2019 have been described by one of Australia\u2019s foremost experts on the drug as crude, sensational and likely to cause undue concern among Australians\u2026.\u201d<\/p>\r\n\r\n\r\n\r\n

That’s the introduction printed in the Australian Ageing Agenda in which Professor Mark Nelson responds to a widely publicised UK aspirin study.<\/p>\r\n\r\n\r\n\r\n

Professor Nelson, a practicing GP and Chief Investigator <\/a>to the ASPREE trial in Tasmania<\/a>, said the UK study was an analysis of combined results of different studies in mostly middle-aged adults and that findings were not generalisable to the older community.<\/p>\r\n\r\n\r\n\r\n

\u201cThere\u2019s a paucity of studies of the elderly and they need to be done because the balance of benefit versus harm is unknown. There are a lot of reasons why the elderly shouldn\u2019t just be looked upon as middle aged individuals who are older, much like we wouldn\u2019t assume medication used in children is the same as when used in adults,\u201d he said.<\/p>\r\n\r\n\r\n\r\n

Read the full interview with the\u00a0Australian Ageing Agenda<\/a>. The UK aspirin study was published in the\u00a0Archives of Internal Medicine<\/a><\/em>.<\/p>\r\n\r\n\r\n\r\n

Updated 1.04.2021<\/em><\/p>\r\n","protected":false},"excerpt":{"rendered":"

ASPREE investigator, Prof Mark Nelson says Australia is ahead in aspirin research, with a clinical trial to answer the question of benefit vs risk in older adults. <\/p>\n","protected":false},"author":2,"featured_media":1750,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"1200","footnotes":""},"categories":[17,18,16],"tags":[80,67],"_links":{"self":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5878"}],"collection":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/comments?post=5878"}],"version-history":[{"count":8,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5878\/revisions"}],"predecessor-version":[{"id":8551,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/5878\/revisions\/8551"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media\/1750"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media?parent=5878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/categories?post=5878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/tags?post=5878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}